Dr. Tara Friedel Carr, MD

Dr. Carr practices at University of Arizona in Tucson, Arizona.

Dr. Carr's NPI, 1669634853, was assigned on June 27, 2008. Dr. Carr graduated from UVA School of Medicine in 2006. Dr. Carr holds Arizona license 44399.

Dr. Carr's primary practice is University of Arizona, at 1501 N Campbell Ave, Tucson, AZ 85724 in Pima County. The practice phone is (520) 626-2761.

Dr. Carr's primary practice is University of Arizona in Tucson, Arizona. Dr. Carr is also affiliated with Banner - University Medical Center Tucson. The medical group on file is Banner Medical Group. Dmand AI also links Dr. Carr to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carr practices, 2 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Carr's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Carr is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Carr's licenses on file in 2 states: Arizona and Illinois.

Dmand AI lists asthma, chronic nasal allergies, chronic sinusitis, hives and immune deficiency disease among the conditions Dr. Carr treats.

CMS data shows 714 Medicare services from Dr. Carr across 5 procedure codes in 2024, for 151 Medicare patients. Medicare paid $14,712 for them. Every service was in an office.

CMS counts 151 Medicare patients who saw Dr. Carr in 2024. The largest group is 65 to 74, with 77 patients. 74% of them have high cholesterol, and 59% have asthma. 9% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carr's median patient age at 62, with 68% women.

In 2024, Dr. Carr wrote 1,203 Medicare Part D claims for 154 patients. CMS names the drug for 1,078 of them, across 33 drugs with 11 or more claims each, at $1,185,838 in total drug cost. In 2023, CMS named 975 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Carr for performance year 2024, reported through an alternative payment model (APM). Dr. Carr accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carr as offering telehealth.

Dmand AI links 75 papers to Dr. Carr, published from 2013 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Asthma, COVID-19 and Allergens. Dr. Carr has published most often in J Allergy Clin Immunol Pract. Dr. Carr's most frequent co-authors are Monica T. Kraft, Fernando D. Martinez, MD and Leonard B. Bacharier, MD.

Dmand AI links Dr. Carr to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Asthma, Aspirin-Induced, Mast Cell Activation Disorders and Drug Hypersensitivity.

CMS Open Payments shows 192 general payments to Dr. Carr from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $58,490. It also lists 3 research payments totaling $6,072 in 2021.

Dr. Carr graduated from UVA School of Medicine in 2006. Dr. Carr is a member of AAAAI.

Dr. Carr is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.